Such an approach may be optimally tailored by choosing a chemokine ligand and receptor matching pair that overlaps with physiological chemokine ligand expression in specific tumours e.g. using CX3CL1/CX3CR1 matching in ovarian cancer [128] or CCL-19/CCR7 matching in breast cancer [212]. Here, CCL19 is linked to neoplasm.